Laurel Venture Capital

Laurel Venture Capital is a venture capital firm headquartered in Hangzhou, China, established in 2017. The firm specializes in equity investments in early and mid-stage life science companies, with a particular focus on therapeutic assets. Its investment strategy emphasizes biotechnology innovations that present promising commercial opportunities, especially in areas such as cancer immunotherapy, gene therapy, and new antibiotics. Laurel Venture Capital targets investments globally, primarily in China, Europe, and the United States. The firm's team comprises experienced professionals with expertise in finance, regulatory affairs, intellectual property, and clinical operations, enabling them to strategically engage with portfolio companies and foster successful partnerships and outcomes.